Article
Hepatitis C protease and polymerase inhibitors in development.
AIDS patient care and STDs - 1 Jun 2008
Liu-Young Gustine, Kozal Michael J
Abstract excerpt
Hepatitis C infection (HCV) remains a global problem and the current anti-HCV therapies available in the clinic have sustained virologic response rates (SVR) of only about 50%, especially in HCV genotype 1-infected subjects. The SVR is even lower in HIV-HCV co-infected patients, estimated at only about 30-40%. However, exciting new research is under way to find new anti-HCV therapies. Presently, efforts to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.